Jason E Faris
Overview
Explore the profile of Jason E Faris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2950
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chapeau E, Sansregret L, Galli G, Chene P, Wartmann M, Mourikis T, et al.
Nat Cancer
. 2024 Jun;
5(7):1130.
PMID: 38886525
No abstract available.
2.
Chapeau E, Sansregret L, Galli G, Chene P, Wartmann M, Mourikis T, et al.
Nat Cancer
. 2024 Apr;
5(7):1102-1120.
PMID: 38565920
The YAP-TEAD protein-protein interaction mediates YAP oncogenic functions downstream of the Hippo pathway. To date, available YAP-TEAD pharmacologic agents bind into the lipid pocket of TEAD, targeting the interaction indirectly...
3.
Schoffski P, Concin N, Suarez C, Subbiah V, Ando Y, Ruan S, et al.
Oncol Res Treat
. 2021 Sep;
44(10):547-556.
PMID: 34515215
Purpose: This first-in-human study (NCT02947152) evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of HKT288, a first-in-class CDH6-targeting antibody-drug conjugate (ADC). Experimental Design: HKT288 was administered intravenously (IV) every 3...
4.
Chaudhary S, Kwak E, Hwang K, Lennerz J, Corcoran R, Heist R, et al.
Oncologist
. 2020 Aug;
25(11):e1691-e1700.
PMID: 32820577
Background: Metastatic esophagogastric cancers (EGCs) have a poor prognosis with an approximately 5% 5-year survival. Additional treatment approaches are needed. c-MET gene-amplified tumors are an uncommon but potentially targetable subset...
5.
Parikh A, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, et al.
Nat Med
. 2019 Nov;
25(12):1949.
PMID: 31745334
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
6.
Parikh A, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, et al.
Nat Med
. 2019 Sep;
25(9):1415-1421.
PMID: 31501609
During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique resistance mechanisms in an individual patient. Previous case reports and small case series have suggested...
7.
Murphy J, Wo J, Ryan D, Clark J, Jiang W, Yeap B, et al.
JAMA Oncol
. 2019 May;
5(7):1020-1027.
PMID: 31145418
Importance: Patients with locally advanced pancreatic cancer have historically poor outcomes. Evaluation of a total neoadjuvant approach is warranted. Objective: To evaluate the margin-negative (R0) resection rate of neoadjuvant FOLFIRINOX...
8.
Murphy J, Wo J, Ryan D, Jiang W, Yeap B, Drapek L, et al.
JAMA Oncol
. 2018 May;
4(7):963-969.
PMID: 29800971
Importance: Patients with borderline-resectable pancreatic ductal adenocarcinoma have historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation of a total neoadjuvant approach with highly active therapy is warranted. Objective:...
9.
Hazar-Rethinam M, Kleyman M, Han G, Liu D, Ahronian L, Shahzade H, et al.
Cancer Discov
. 2018 Feb;
8(4):417-427.
PMID: 29431697
Clonal heterogeneity associated with acquired resistance presents a critical therapeutic challenge. Whole-exome sequencing of paired tumor biopsies and targeted sequencing of cell-free DNA (cfDNA) from patients with colorectal cancer receiving...
10.
Bialucha C, Collins S, Li X, Saxena P, Zhang X, Durr C, et al.
Cancer Discov
. 2017 May;
7(9):1030-1045.
PMID: 28526733
Despite an improving therapeutic landscape, significant challenges remain in treating the majority of patients with advanced ovarian or renal cancer. We identified the cell-cell adhesion molecule cadherin-6 () as a...